Earnings summaries and quarterly performance for Sana Biotechnology.
Executive leadership at Sana Biotechnology.
Board of directors at Sana Biotechnology.
Research analysts covering Sana Biotechnology.
Recent press releases and 8-K filings for SANA.
Sana Biotechnology, Inc. Provides Program Updates at J.P. Morgan Healthcare Conference
SANA
New Projects/Investments
Product Launch
- Sana Biotechnology, Inc. discussed its updated corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
- The company reported that UP421, a hypoimmune primary pancreatic islet cell therapy, continued to survive, evade immune detection, and function 12 months post-transplantation in a type 1 diabetes patient without immunosuppression.
- Sana remains on track to file an investigational new drug application (IND) and begin a Phase 1 trial for SC451, a HIP-modified iPSC-derived pancreatic islet cell therapy, as early as 2026.
- The company aims to generate initial human data as early as 2026 for SG293, an in vivo CD19-directed CAR T cell therapy, with the first trial likely in blood cancers.
Jan 14, 2026, 5:45 PM
Sana to File IND for Type 1 Diabetes Therapy and Initiate CAR T Trials in 2026
SANA
New Projects/Investments
Product Launch
Guidance Update
- Sana plans to file its Investigational New Drug (IND) application and commence a Phase I study for its Type 1 Diabetes (T1D) therapy (SC451) in 2026, aiming for a functional cure with rapid proof of concept.
- The company reported positive human data from a clinical study where gene-modified cadaveric islets, designed to evade immune rejection, survived and functioned for over a year in a T1D patient without immunosuppression.
- Sana has developed a "best-in-class" in vivo CAR T platform and expects to initiate its first clinical trial for this platform in 2026, likely starting in cancer before moving to autoimmune diseases, with clinical data anticipated this year.
- The company indicated that its CAR T platform would benefit from a partnership over time, particularly after generating human data, due to capital constraints and the desire to accelerate development across multiple targets.
Jan 14, 2026, 5:45 PM
Sana Outlines 2026 Clinical Development Plans for Type 1 Diabetes and CAR T Programs
SANA
New Projects/Investments
Guidance Update
- Sana plans to file an Investigational New Drug (IND) application for its type 1 diabetes therapy (SC451) and begin a Phase 1 study in 2026, aiming for a functional cure without immunosuppression.
- The company reported positive human data from a low-dose, first-in-human study for type 1 diabetes, demonstrating immune evasion and continued C-peptide production in a patient over a year, with no drug-related adverse events.
- Sana has developed a gene-modified master cell bank for pancreatic beta cells, addressing genomic stability concerns and aligning with global regulators.
- For its in vivo CAR T cell program, Sana expects to deliver data in 2026 and plans to initiate its first clinical trial this year, starting in cancer and rapidly moving into autoimmune diseases.
Jan 14, 2026, 5:45 PM
Sana Outlines 2026 Clinical Development Plans for Type 1 Diabetes and CAR T-Cell Therapies
SANA
New Projects/Investments
Guidance Update
- Sana plans to file an Investigational New Drug (IND) application and initiate a Phase 1 study this year (2026) for its Type 1 Diabetes (T1D) therapy, SC451, which aims for a functional cure without immunosuppression.
- Initial human data for the T1D program shows a patient over a year post-treatment with surviving and functioning gene-modified cells, detectable C-peptide, and no evidence of immune rejection or drug-related adverse events.
- Sana also expects to begin its first in vivo CAR T-cell trial this year (2026), initially in cancer, with plans to rapidly move into autoimmune diseases, and anticipates reporting clinical data in 2026.
- Preclinical data for the in vivo CAR T platform demonstrates exquisitely specific T-cell delivery and, in non-human primates, dose-dependent CAR T-cell expansion and complete B-cell depletion.
- The company highlighted significant manufacturing scale-up challenges for its T1D therapy, moving from Phase 1 (10-15 patients) to commercialization (10 million people), focusing on maintaining purity and genomic stability.
Jan 14, 2026, 5:45 PM
Sana Biotechnology Outlines 2026 Clinical Goals and 2025 Program Progress
SANA
New Projects/Investments
Product Launch
Guidance Update
- Sana Biotechnology made significant progress in 2025 on its Type 1 diabetes program, including immune evasion, regulatory interactions, and manufacturing.
- For 2026, Sana's goal is to file an IND and start a Phase 1 trial for SC451 (Type 1 diabetes) and to achieve initial first-in-human data for SG293 (in vivo CAR T cell program).
- The company has demonstrated clinical validation of its hypoimmune islet cells (UP421) in a Type 1 diabetes patient, showing immune evasion and function without immunosuppression for 12 months.
Jan 14, 2026, 5:00 PM
Sana discusses Type 1 Diabetes program SC451 and in vivo CAR T advancements
SANA
New Projects/Investments
Product Launch
- Sana's primary focus is SC451, a program aiming for a functional cure for Type 1 Diabetes by transplanting gene-modified islets that persist and function without immunosuppression.
- Early human data from a clinical study in Sweden demonstrated that one patient treated with gene-modified islets showed stable C-peptide levels and insulin production over six months without immunosuppression.
- An Investigational New Drug (IND) application for SC451 is expected in 2026, with a Phase 1 study planned to enroll 12-15 patients.
- Sana is also developing an in vivo CAR T program that uses a virus-like particle (VLP) for cell-specific delivery of a DNA plasmid, which has shown promising B cell depletion and CAR-T cell expansion in non-human primates.
- The company believes that future clinical data from the SC451 program could qualify for a breakthrough designation.
Dec 3, 2025, 7:35 PM
Sana Biotechnology Details Progress on Type 1 Diabetes Functional Cure and In Vivo CAR-T Programs
SANA
New Projects/Investments
Product Launch
- Sana Biotechnology is developing SC451 as a potential functional cure for Type 1 diabetes, aiming for a single treatment that eliminates the need for insulin, monitoring, and immunosuppression.
- The company anticipates filing an Investigational New Drug (IND) application for SC451 next year, with studies potentially commencing in 2026.
- A key advancement for SC451 involves gene-modified islets that demonstrate persistence and function without immunosuppression, a significant improvement over existing stem cell-derived islet transplants that require it.
- Sana's immune evasion strategy for its cell therapies involves overexpressing CD47 while knocking out MHC class I and II, which has been shown to protect cells from various immune attacks in multiple models and human contexts.
- The company also highlighted its in vivo CAR-T program, which utilizes a virus-like particle (VLP) for cell-specific delivery of a DNA plasmid, demonstrating promising results in non-human primates including CAR-T cell expansion and B cell depletion.
Dec 3, 2025, 7:35 PM
Sana Biotechnology Discusses Type 1 Diabetes Program and In Vivo CAR-T Development
SANA
New Projects/Investments
Guidance Update
- Sana Biotechnology's primary focus is on SC451, a drug aiming for a functional cure of Type 1 diabetes designed to eliminate the need for insulin and immunosuppression.
- The company anticipates filing an Investigational New Drug (IND) application for SC451 in 2026, with plans for a Phase I study to enroll 12-15 patients.
- SC451 utilizes gene-modified pluripotent stem cells, with a target dose of approximately one billion cells per patient to achieve euglycemia, though manufacturing challenges include ensuring genomic stability and product purity.
- Sana is also advancing an in vivo CAR-T program, which uses a virus-like particle (VLP) for cell-specific delivery of a DNA plasmid and has demonstrated effective B cell depletion in non-human primates.
Dec 3, 2025, 7:35 PM
Sana Biotechnology Outlines Pipeline Strategy and Clinical Timelines for T1D and In Vivo CAR T Programs
SANA
New Projects/Investments
Guidance Update
Product Launch
- Sana Biotechnology has streamlined its pipeline to prioritize SC451, a T1D islet cell product, and SG293, an in vivo CAR T product.
- The company targets filing an IND and initiating a clinical study for SC451 in 2026, following the successful establishment of a GMP master cell bank.
- For the in vivo CAR T program (SG293), while the current IND guidance is 2027, Sana is exploring avenues to obtain human data as early as 2026 by potentially starting trials in other regions.
- Sana is considering partnerships for its in vivo CAR T platform to accelerate development and capital, but plans to advance the T1D program through Phase I proof of concept independently.
Dec 2, 2025, 7:30 PM
Sana Biotechnology Discusses Pipeline Focus and Clinical Timelines
SANA
New Projects/Investments
Guidance Update
- Sana Biotechnology is streamlining its pipeline to concentrate on two key programs: SC451, a Type 1 Diabetes (T1D) pilot cell product, and SG293, an in vivo CAR-T product.
- For the SC451 T1D program, the company's goal is to file an Investigational New Drug (IND) application and commence a clinical study next year (2026), following the successful development of a gene-modified pluripotent master cell bank.
- The company has provided guidance for a 2027 IND for its SG293 in vivo CAR-T program, but is exploring avenues to obtain human data as early as next year (2026) by potentially initiating studies in different geographies.
- While Sana can finance its programs independently, especially through Phase 1 for Type 1 Diabetes, it anticipates that manufacturing scale-up for SC451 and the commercialization of curative therapies will likely necessitate a partnership.
Dec 2, 2025, 7:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more